MannKind Corporation Revenue and Competitors

MannKind is a biopharmaceutical company focused on the development and commercialization of therapeutic products for diseases such as diabetes, cancer, inflammatory, and autoimmune diseases. Our lead product, the Technosphere® Insulin System, which is currently in Phase IIb clinical trials for the treatment of diabetes, consists of our dry-powder Technosphere® formulation of insulin and our MedTone inhaler through which the powder is inhaled into the deep lung. We believe the performance characteristics, convenience and ease of use of our proprietary Technosphere® Insulin System have the potential to change the way diabetes is treated. Our Technosphere® research activities are complemented by additional efforts aimed at the discovery and development of novel drugs. We are developing additional applications for our proprietary Technosphere® formulation technology by formulating other drugs for pulmonary delivery, primarily for metabolic and immunological diseases. We are also developing therapies for the treatment of solid-tumor cancers. MannKind's corporate headquarters and our immunology research operations are located in Valencia, California. We are also located in Danbury, Connecticut, which is where we conduct most of our Technosphere® Insulin research, development and manufacturing.

keywords:Biotechnology, Healthcare